Company news
Theriva Biologics, Inc. (AMEX:TOVX) news
Theriva Biologics, Inc. news releases on 6ix. Latest, Aug 12, 2026: Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
Press releases & updates
Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
August 12, 2026
Theriva Biologics: Q2 Earnings Snapshot
August 11, 2026
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
August 11, 2026
Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
August 7, 2026
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
August 6, 2026
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
July 7, 2026
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
May 5, 2026
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
April 17, 2026
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
March 23, 2026
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
March 12, 2026
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
February 18, 2026
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
February 3, 2026
Theriva Biologics Announces Positive Scientific Advice from the European Medicines Agency on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
December 30, 2025
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
December 29, 2025
Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results
November 12, 2025
Theriva Biologics Provides Response to Unusual Market Action
October 24, 2025
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
October 16, 2025
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings
October 13, 2025
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 6, 2025
Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
August 12, 2025
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
August 11, 2025
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
May 27, 2025
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
May 14, 2025
Theriva Biologics Announces Closing of $7.5 Million Public Offering
May 8, 2025
Theriva Biologics Announces Pricing of $7.5 Million Public Offering
May 7, 2025
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients
May 7, 2025